$CLRB News

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO

Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders

Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

Cellectar (CLRB) Q1 2026 Earnings Transcript

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call

Cellectar Biosciences Q1 EPS $(1.33) Beats $(1.89) Estimate. Cash And Equivalents $8.35M

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know

What's Going With Cellectar Biosciences Stock On Wednesday?

Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

Cellectar Biosciences Phase 2b CLOVER WaM 12-Month Data Shows 83.6% ORR And Durable Responses Exceeding 18 Months In Post-BTKi Patients

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Cellectar Biosciences Announces The Acceptance Of An Abstract For Poster Presentation At The American Society Of Clinical Oncology Annual Meeting Taking Place May 29 - June 2 In Chicago, Illinois